Susquehanna Fundamental Investments LLC Invests $3.18 Million in AtriCure, Inc. (NASDAQ:ATRC)

Susquehanna Fundamental Investments LLC acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 104,094 shares of the medical device company's stock, valued at approximately $3,181,000. Susquehanna Fundamental Investments LLC owned about 0.21% of AtriCure as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ATRC. Blue Trust Inc. increased its holdings in AtriCure by 1.8% in the fourth quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after buying an additional 265 shares during the last quarter. Invesco Ltd. increased its holdings in shares of AtriCure by 0.8% in the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after acquiring an additional 334 shares during the last quarter. Perkins Capital Management Inc. raised its position in shares of AtriCure by 1.3% during the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after acquiring an additional 400 shares in the last quarter. Truist Financial Corp raised its position in shares of AtriCure by 2.6% during the 4th quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock valued at $480,000 after acquiring an additional 403 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in AtriCure by 0.9% during the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock worth $1,569,000 after purchasing an additional 484 shares during the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. BTIG Research reissued a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. Stifel Nicolaus increased their price objective on shares of AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Needham & Company LLC decreased their target price on AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Oppenheimer increased their price target on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Finally, Piper Sandler boosted their price objective on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, AtriCure presently has an average rating of "Moderate Buy" and a consensus target price of $50.67.

Insider Buying and Selling

In other news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.50% of the stock is owned by corporate insiders.

AtriCure Stock Performance

Shares of ATRC traded down $0.89 during trading hours on Monday, reaching $29.14. 166,593 shares of the company's stock traded hands, compared to its average volume of 652,733. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -30.47 and a beta of 1.65. The business's fifty day simple moving average is $33.57 and its two-hundred day simple moving average is $34.77. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.11. The firm had revenue of $123.62 million for the quarter, compared to analysts' expectations of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. AtriCure's quarterly revenue was up 13.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.28) EPS. Analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.